ABSTRACT
Introduction While the incidence of HIV declines in most age groups globally, it continues to rise among adolescents and young adults who also experience a higher rate of HIV-related deaths. These tech-savvy individuals might benefit from an online patient portal aimed at increasing awareness, building skills, and promoting patient activation – the willingness and capacity to independently manage their health. However, the impact of such portals on young HIV patients in Kenya remains uncertain.
Methods and analysis HIV patients aged 15-24 with smartphone access will participate in a 12-month stepped wedge cluster randomized trial. The main focus will be the portal’s effect on patient activation, with secondary outcomes being self-reported adherence, viral suppression, and social involvement. The study also aims to understand the portal’s development, implementation, functionality, usability, and cost. From 47 antiretroviral therapy (ART) sites with electronic medical recording systems, 16 clusters of 30 participants each will be formed. These clusters, over 12 months, will be randomized into 3 intervention sequences every 3 months. Baseline measurements, covering patient activation, adherence, viral load, and social engagement, will be recorded over two weeks, with subsequent checks at 3, 6, and 12 months. Data will be analyzed using generalised linear mixed models.
Ethics and dissemination The protocol has received approval from the AMREF Health Africa Ethics & Scientific Review Committee (ESRC) and local governments. Findings will be shared through stakeholder forums, conferences, publications, and media.
What is the issue?HIV infections among teenagers and young adults are increasing, particularly in Kenya. Given their technological inclination, an online portal might help them manage their health. The effectiveness of this approach remains uncertain.
What are our actions?We are running a year-long study in Kenya with HIV-positive individuals aged 15 to 24 who have smartphones. The goal is to see if the portal aids their health management. We’re assessing health readiness, medication adherence, HIV control, and social connection. The study involves groups from 47 HIV treatment centers, with new groups engaging with the portal every three months.
What are our assessment methods?We will use statistical methods to gauge the portal’s impact on health management.
Is the study approved?Yes. It has endorsements from AMREF Health Africa and local governments. Results will be shared with the community, at conferences, in scientific journals, and in the media.
Competing Interest Statement
Randeep Gill and Sanne Roles, two of the authors, work for Johnson and Johnson, which funded the study. They both contributed to the study's design and conceptual framework.
Clinical Trial
PACTR202303729957231 Pan African Clinical Trial Registry (www.pactr.org) database
Funding Statement
The Johnson and Johnson Foundation provided some of the funding for this study. This funding was used for recruiting and training research assistants, providing airtime for participants, organizing workshops, and developing an online portal along with its specialized content. Two of the study's authors are associated with Johnson and Johnson and were involved in the initial planning and design of the research. However, their involvement ended once the study received ethical approval and began. Johnson and Johnson had no involvement in the actual execution of the study and will not participate in the data analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AMREF Health Africa Ethics & Scientific Review Committee (ESRC) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to correct spelling errors in the abstract
Data Availability
This is a protocol and data will be fully available on analysis.
